It’s abundantly clear that all the key clinical programs are progressing exceptionally well and corporately the board has ensured the balance sheet is robust to weather the current economic environment. Aussie $37.1M of cash, and operating within your highly efficient R&D jurisdiction.
OSA looks to be a company maker, however I’m increasingly of the view that IHL-675A might be an even greater market opportunity.
This is a sensational update and IMO any short term thinking will dissipate in better market conditions. Negatively is just human nature and while I understand this attitude it’s also irrelevant if you have a well researched view of the fundamentals and management. My greatest disappointment is not being able to capitalise on the options as I’m based in the US.
IHL Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held